# Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

> **NCT00753220** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bostwick Laboratories** · enrollment: 7 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** VDC2008
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00753220
- **Lead sponsor:** Bostwick Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Withdrew the IND with the FDA.
- **Last updated:** 2014-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753220, "Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00753220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*